The estimated Net Worth of Renaud Bertrand Maloberti is at least $74.3 millier dollars as of 12 January 2021. Mr. Maloberti owns over 20,000 units of ENDRA Life Sciences Inc stock worth over $395 and over the last 5 years he sold NDRA stock worth over $73,950. In addition, he makes $0 as Chief Commercial Officer at ENDRA Life Sciences Inc.
Sign up
Mr. Maloberti NDRA stock SEC Form 4 insiders trading
Renaud has made over 6 trades of the ENDRA Life Sciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of NDRA stock worth $21,600 on 12 January 2021.
The largest trade he's ever made was selling 25,000 units of ENDRA Life Sciences Inc stock on 17 December 2020 worth over $18,250. On average, Renaud trades about 7,083 units every 9 days since 2019. As of 12 January 2021 he still owns at least 1,580 units of ENDRA Life Sciences Inc stock.
You can see the complete history of Mr. Maloberti stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Renaud Maloberti biography
Renaud Bertrand Maloberti serves as Chief Commercial Officer of the Company. He brings over 20 years of global commercial experience in medical imaging, including 12 years in ultrasound. Most recently, Mr. Maloberti was Chief Commercial Officer of Bionik Laboratories, a company in the AI-enhanced rehabilitation robotics market. From 2012 to 2018, Mr. Maloberti held various positions at FujiFilm SonoSite Inc., most recently as vice president and general manager of the SonoSite High Frequency division, where he led the development and launch of the world's first ultra-high frequency ultrasound and led the division through double-digit revenue growth for six years. Mr. Maloberti previously served as general manager, Americas for BK Medical Systems, the ultrasound subsidiary of Analogic Corporation (Nasdaq: ALOG). Earlier in his career, Mr. Maloberti worked at Draeger Medical Systems, a leader in patient monitoring and healthcare IT systems. Mr. Maloberti also spent 10 years in sales and marketing roles at GE Healthcare, a global leader in diagnostic imaging, healthcare IT systems and services. Maloberti holds an M.B.A. in global marketing from Babson College and a bachelor’s degree in International Finance from ESLSCA Business School in Paris, France. He is fluent in English and French.
How old is Renaud Maloberti?
Renaud Maloberti is 51, he's been the Chief Commercial Officer of ENDRA Life Sciences Inc since 2019. There are 8 older and 1 younger executives at ENDRA Life Sciences Inc. The oldest executive at ENDRA Life Sciences Inc is Michael Harsh, 65, who is the Independent Director.
What's Renaud Maloberti's mailing address?
Renaud's mailing address filed with the SEC is C/O ENDRA LIFE SCIENCES INC., 3600 GREEN COURT, SUITE 350, ANN ARBOR, MI, 48105.
Insiders trading at ENDRA Life Sciences Inc
Over the last 8 years, insiders at ENDRA Life Sciences Inc have traded over $893,199 worth of ENDRA Life Sciences Inc stock and bought 413,648 units worth $301,877 . The most active insiders traders include Group Ag Ubs, Capital Advisors, Llc Conra... et Alexander Y Tokman. On average, ENDRA Life Sciences Inc executives and independent directors trade stock every 61 days with the average trade being worth of $5,922. The most recent stock trade was executed by Group Ag Ubs on 27 August 2024, trading 3,715 units of NDRA stock currently worth $2,043.
What does ENDRA Life Sciences Inc do?
endra life sciences is bringing new capabilities to ultrasound. our photo-acoustic solutions help medical researchers screen and modify disease models with unparalleled quality and speed. we’re proud to have a global installed base of leading institutions using our nexus-128 system, the only 3d imaging solution for imaging anatomy, physiology and labeled molecular targets. the nexus 128 is a preclinical photoacoustic computed tomography (ct) scanner for small animal imaging. the system is used for simple, fast, non-invasive quantification of physiological parameters such as tumor vasculature without ionizing radiation. the fully-3d imaging technology used by the nexus 128 provides increased sensitivity compared to slice-based scanners, and dynamic (4-d) photoacoustic ct scans allow for applications such as quantification of probe uptake. the nexus 128 is currently being used by top imaging laboratories around the globe.
What does ENDRA Life Sciences Inc's logo look like?
Complete history of Mr. Maloberti stock trades at ENDRA Life Sciences Inc
ENDRA Life Sciences Inc executives and stock owners
ENDRA Life Sciences Inc executives and other stock owners filed with the SEC include:
-
Francois Michelon,
Chairman of the Board, Chief Executive Officer -
Michael Thornton,
Chief Technology Officer -
David Wells,
Chief Financial Officer -
Michael Thornton,
Chief Technology Officer -
David R. Wells,
CFO & Sec. -
Joe Hassett,
Investors Relation -
Louis Basenese,
Independent Director -
Alexander Tokman,
Independent Director -
Michael Harsh,
Independent Director -
Sanjiv Gambhir,
Independent Director -
Anthony DiGiandomenico,
Independent Director -
Renaud Maloberti,
Chief Commercial Officer -
Steve Freeman,
HR Leader -
Dr. Jonathan Behr,
Co-Founder -
Capital Advisors, Llc Conra...,
-
Group Ag Ubs,
10% owner -
Lou Basenese,
Director -
Irina Pestrikova,
Senior Director, Finance